Cargando…
Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149582/ https://www.ncbi.nlm.nih.gov/pubmed/34037927 http://dx.doi.org/10.1007/s10654-021-00758-0 |
_version_ | 1783697975692754944 |
---|---|
author | Dror, Amiel A. Daoud, Amani Morozov, Nicole G. Layous, Eli Eisenbach, Netanel Mizrachi, Matti Rayan, Doaa Bader, Ahmad Francis, Shawky Kaykov, Edward Barhoum, Masad Sela, Eyal |
author_facet | Dror, Amiel A. Daoud, Amani Morozov, Nicole G. Layous, Eli Eisenbach, Netanel Mizrachi, Matti Rayan, Doaa Bader, Ahmad Francis, Shawky Kaykov, Edward Barhoum, Masad Sela, Eyal |
author_sort | Dror, Amiel A. |
collection | PubMed |
description | Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life science graduates (biology, virology, chemistry, etc.), and the general public to whether they would obtain a COVID-19 vaccine with particular vaccine characteristics such as vaccine country of origin, technology, side effect profile, efficacy, and other attributes. Physicians and life science graduates were least likely to accept a vaccine based on mRNA technology (30%) while the general population seemed to adopt any vaccine technology if the declared efficacy is above 90% and the country of manufacturing is the USA/UK rather than China or Russia. However, current inoculation rates in Israel far outpace our predicted rate. Our results highlight the importance of tailored vaccine educational campaigns based on population demographic details and specific vaccine concerns. |
format | Online Article Text |
id | pubmed-8149582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-81495822021-05-26 Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification Dror, Amiel A. Daoud, Amani Morozov, Nicole G. Layous, Eli Eisenbach, Netanel Mizrachi, Matti Rayan, Doaa Bader, Ahmad Francis, Shawky Kaykov, Edward Barhoum, Masad Sela, Eyal Eur J Epidemiol Covid-19 Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life science graduates (biology, virology, chemistry, etc.), and the general public to whether they would obtain a COVID-19 vaccine with particular vaccine characteristics such as vaccine country of origin, technology, side effect profile, efficacy, and other attributes. Physicians and life science graduates were least likely to accept a vaccine based on mRNA technology (30%) while the general population seemed to adopt any vaccine technology if the declared efficacy is above 90% and the country of manufacturing is the USA/UK rather than China or Russia. However, current inoculation rates in Israel far outpace our predicted rate. Our results highlight the importance of tailored vaccine educational campaigns based on population demographic details and specific vaccine concerns. Springer Netherlands 2021-05-26 2021 /pmc/articles/PMC8149582/ /pubmed/34037927 http://dx.doi.org/10.1007/s10654-021-00758-0 Text en © Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Dror, Amiel A. Daoud, Amani Morozov, Nicole G. Layous, Eli Eisenbach, Netanel Mizrachi, Matti Rayan, Doaa Bader, Ahmad Francis, Shawky Kaykov, Edward Barhoum, Masad Sela, Eyal Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title | Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title_full | Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title_fullStr | Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title_full_unstemmed | Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title_short | Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
title_sort | vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149582/ https://www.ncbi.nlm.nih.gov/pubmed/34037927 http://dx.doi.org/10.1007/s10654-021-00758-0 |
work_keys_str_mv | AT droramiela vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT daoudamani vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT morozovnicoleg vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT layouseli vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT eisenbachnetanel vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT mizrachimatti vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT rayandoaa vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT baderahmad vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT francisshawky vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT kaykovedward vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT barhoummasad vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification AT selaeyal vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification |